PCV2B divergent vaccine composition and methods of use
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/12
A61K-045/06
A61K-039/39
C12N-007/00
A61K-039/00
출원번호
US-0917620
(2014-09-24)
등록번호
US-9987348
(2018-06-05)
국제출원번호
PCT/US2014/057190
(2014-09-24)
국제공개번호
WO2015/048115
(2015-04-02)
발명자
/ 주소
Nitzel, Gregory Paul
Slade, David Ewell
출원인 / 주소
Zoetis Services LLC
대리인 / 주소
Szakiel, Gloria K.
인용정보
피인용 횟수 :
0인용 특허 :
99
초록▼
This invention provides a vaccine composition for protecting pigs against PCV2, including a highly virulent porcine circovirus type 2b (PCV2b) divergent strain, the composition including a PCV2b divergent ORF2 polypeptide, wherein the ORF2 polypeptide comprises Leucine (L) at position 89, Threonine
This invention provides a vaccine composition for protecting pigs against PCV2, including a highly virulent porcine circovirus type 2b (PCV2b) divergent strain, the composition including a PCV2b divergent ORF2 polypeptide, wherein the ORF2 polypeptide comprises Leucine (L) at position 89, Threonine (T) at position 90, and Aspargine (N) at position 134, according to the numbering of SEQ ID NO: 1 herein.
대표청구항▼
1. A vaccine composition for protecting pigs against PCV2, including a highly virulent porcine circovirus type 2b (PCV2b) divergent strain, the composition comprising a PCV2b ORF2 polypeptide encoded by a PCV2b divergent strain having at least 95% sequence identity with SEQ ID NO: 66, wherein the OR
1. A vaccine composition for protecting pigs against PCV2, including a highly virulent porcine circovirus type 2b (PCV2b) divergent strain, the composition comprising a PCV2b ORF2 polypeptide encoded by a PCV2b divergent strain having at least 95% sequence identity with SEQ ID NO: 66, wherein the ORF2 polypeptide comprises Leucine (L) at position 89, Threonine (T) at position 90, and Asparagine (N) at position 134, according to the numbering of SEQ ID NO: 1; and an oil-in-water emulsion adjuvant. 2. The composition of claim 1, wherein the composition is in the form of an inactivated, PCV2b divergent whole virus that comprises the PCV2b ORF2 polypeptide as its viral capsid. 3. The composition of claim 1, wherein the composition is in the form of an inactivated chimeric porcine circovirus type 1-type2 whole virus, wherein said chimeric porcine circovirus comprises an inactivated recombinant porcine circovirus type 1 that comprises the PCV2b ORF2 polypeptide in place of the ORF2 capsid of PCV1. 4. The composition of claim 1, wherein the composition is in the form of an isolated, recombinant PCV2b ORF2 polypeptide. 5. The composition of claim 4, wherein the composition further includes an expression vector. 6. The composition of claim 5, wherein the vector is baculovirus or parapoxvirus. 7. The composition of claim 5, wherein the vector is a live or inactivated vector. 8. The composition of claim 1, wherein the PCV2b ORF2 polypeptide further comprises at least one residue selected from the group consisting of: a Lysine (K) at residue 59, a Lysine (K) at residue 234, a Threonine (T) at residue 190, an Isoleucine (I) at residue 53, an Asparagine (N) at residue 68, an Arginine (R) or Glycine (G) at residue 169, and an Isoleucine (I) at residue 215 according to the numbering of SEQ ID NO: 1. 9. The composition of claim 1, wherein the PCV2b ORF2 polypeptide further comprises a Lysine (K) at residue 59 and a Lysine (K) at residue 234 according to the numbering of SEQ ID NO: 1. 10. The composition of claim 9, wherein the PCV2b ORF2 polypeptide further comprises a Threonine (T) at residue 190, an Isoleucine (I) at residue 53, an Asparagine (N) at residue 68, an Arginine (R) or Glycine (G) at residue 169, and an Isoleucine (I) at residue 215 according to the numbering of SEQ ID NO: 1. 11. The composition of claim 1, wherein the PCV2 ORF2 polypeptide is represented by the amino acid sequence of SEQ ID NO: 1, or an immunogenic portion thereof corresponding to a truncated form of the ORF2 polypeptide. 12. The composition of claim 1, further comprising at least one additional porcine antigen. 13. The composition of claim 12, wherein the at least one additional antigen is protective against a disease in pigs caused by a microorganism. 14. The composition of claim 13, wherein the microorganism comprises a bacterium, virus, or protozoan. 15. The composition of claim 14, wherein the microorganism is selected from the group consisting of Mycoplasma hyopneumoniae (M. hyo), porcine reproductive and respiratory syndrome virus (PRRSV), porcine parvovirus (PPV), Haemophilus parasuis, Pasteurella multocida, Streptococcum suis, Staphylococcus hyicus, Actinobacilllus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Salmonella enteritidis, Erysipeiothrix rhusiopathiae, Mycoplama hyorhinis, Mycoplasma hyosynoviae, leptospira bacteria, Lawsonia intracellularis, swine influenza virus (SIV), Escherichia coli antigen, Brachyspira hyodysenteriae, porcine respiratory coronavirus, Porcine Epidemic Diarrhea (PED) virus, rotavirus, Porcine enteroviruses, Encephalomyocarditis virus, a pathogen causative of Aujesky's Disease, Classical Swine fever (CSF) and a pathogen causative of Swine Transmissible Gastroenteritis, or combinations thereof. 16. The composition of claim 1, wherein the oil-in-water emulsion adjuvant is based on squalane and comprises a block copolymer. 17. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier. 18. A method of immunizing a pig against PCV2, including a highly virulent PCV2b divergent strain, the method comprising administering to the pig the composition of claim 1. 19. The method of claim 18, wherein the composition is administered intranasally, intramuscularly, intradermally, transdermally, subcutaneously, or orally. 20. The method of claim 18, wherein the composition is administered in a single dose. 21. The method of claim 18, wherein the composition is administered as two doses. 22. The method of claim 18, wherein the composition is administered to pigs having maternally-derived antibodies against PCV2. 23. The method of claim 18, wherein the composition is administered to pigs at 3 weeks of age or older. 24. A kit comprising: a bottle comprising a vaccine composition for protecting pigs against PCV2, including a highly virulent porcine circovirus type 2b (PCV2b) divergent strain, the composition comprising a PCV2b ORF2 polypeptide encoded by a PCV2b divergent strain having at least 95% sequence identity with SEQ ID NO: 66, wherein the ORF2 polypeptide comprises Leucine (L) at position 89, Threonine (T) at position 90, and Asparagine (N) at position 134 according to the numbering of SEQ ID NO: 1, and an oil-in-water emulsion adjuvant. 25. The kit of claim 24, wherein the PCV2b divergent ORF2 polypeptide further comprises at least one residue selected from the group consisting of: a Lysine (K) at residue 59, a Lysine (K) at residue 234, a Threonine (T) at residue 190, an Isoleucine (I) at residue 53, an Asparagine (N) at residue 68, an Arginine (R) or Glycine (G) at residue 169, and an Isoleucine (I) at residue 215 according to the numbering of SEQ ID NO: 1. 26. The kit of claim 25, wherein the composition in the bottle is provided as a ready-to-use liquid composition. 27. The kit of claim 24, wherein the composition is provided in a lyophilized form. 28. The kit of claim 27, further comprising a diluent.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (99)
Neurath Alexander Robert ; Jiang Shibo ; Debnath Asim Kumar ; Strick Nathan ; Dow Gordon Jay, "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections".
Paoletti Enzo ; Perkus Marion E. ; Taylor Jill ; Tartaglia James ; Norton Elizabeth K. ; Riviere Michel,FRX ; de Taisne Charles,FRX ; Limbach Keith J. ; Johnson Gerard P. ; Pincus Steven E. ; Cox Wil, Alvac canarypox virus recombinants comprising heterlogous inserts.
Baker Paul E. (Bainbridge Island WA) Cerretti Douglas P. (Seattle WA) Clevenger William R. (Seattle WA) Cosman David J. (Seattle WA) Maliszewski Charles R. (Seattle WA), Bovine granulocyte-macrophage colony stimulating factor.
Harris David J. ; Lee Edward R. ; Siegel Craig S. ; Cheng Seng H. ; Eastman Simon J. ; Marshall John ; Scheule Ronald K., Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules.
Felgner Philip L. (Rancho Santa Fe CA) Kumar Raj (San Diego CA) Basava Channa (San Diego CA) Border Richard C. (Poway CA) Hwang-Felgner Jiin-Yu (Rancho Santa Fe CA), Cationic lipids for intracellular delivery of biologically active molecules.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Van Woensel Petrus Alphonsus Maria,NLX ; Demaret Jean Guillaume Joseph,NLX, European vaccine strains of the porcine reproductive and respiratory syndrome virus.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon Asher (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert Wallace (Davis CA) Carson Dennis A. (Del Mar CA), Generation of antibodies through lipid mediated DNA delivery.
Dubensky ; Jr. Thomas W. ; Polo John M. ; Chang Steven M.W. ; Jolly Douglas J., Method for stimulating an immune response utilizing recombinant alphavirus particles.
Eppstein Deborah A. (Menlo Park CA) Felgner Philip L. (Los Altos CA) Gadek Thomas R. (Oakland CA) Jones Gordon H. (Cupertino CA) Roman Richard B. (Fairhope AL), N-(www
상세보기
Eppstein Deborah A. (Menlo Park CA) Felgner Philip L. (Los Altos CA) Gadek Thomas R. (Oakland CA) Jones Gordon H. (Cupertino CA) Roman Richard B. (Fairhope AL), N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor.
Garvey David S. ; Letts L. Gordon ; Renfroe H. Burt ; Tam Sang William, Nitroso esters of .beta.-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs.
Allan Gordon Moore,GBX ; Meehan Brian Martin,GBX ; Ellis John Albert,CAX ; Krakowka George Steven ; Audonnet Jean-ChrJistophe Francis,FRX, Porcine circovirus and paravovirus vaccine.
Allan, Gordon Moore; Meehan, Brian Martin; Ellis, John Albert; Krakowka, George Steven; Audonnet, Jean-ChrJistophe Francis, Porcine circovirus and parvovirus vaccine.
Gordon Allan GB; Brian Meehan GB; Edward Clark CA; John Ellis CA; Deborah Haines CA; Lori Hassard CA; John Harding CA; Catherine Elisabeth Charreyre FR; Gilles Emile Chappuis FR; Francis McN, Porcine circovirus vaccine and diagnostics reagents.
Gordon Allan GB; Brian Meehan GB; Edward Clark CA; John Ellis CA; Deborah Haines CA; Lori Hassard CA; John Harding CA; Catherine Elisabeth Charreyre FR; Gilles Emile Chappuis FR; Francis McN, Porcine circoviruses vaccines diagnostic reagents.
Sanderson Thomas (Ames IA) McGinley Michael J. (Lenexa KS) Zimmerman Jeffrey J. (Ames IA) Hill Howard T. (Cambridge IA) Meetz Michael C. (Nevada IA) Pirtle Eugene C. (Ames IA) Swenson Sabrina L. (Mad, Porcine reproductive and respiratory syndrome virus antigen and processes for the preparation and use of said antigen in.
Peakman Timothy C. (Beckenham GBX) Page Martin J. (Beckenham GBX) Charles Ian G. (Beckenham GBX), Procaryotic leader sequence in recombinant baculovirus expression system.
Plana Duran Juan,ESX ; Casal Alvarez Jose Ignacio,ESX ; Climent Sanchez Isabel,ESX, Recombinant PRRSV proteins, diagnostic kits and vaccines containing such recombinant PRRSV proteins.
Wasmoen Terri ; Chu Hsien-Jue ; Chavez Lloyd, Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
Casal Alvarez Jose I. (Madrid ESX) Cortes Valdes Elena (Madrid ESX) Ranz Casares Ana I. (Madrid ESX) Vela Olmo Carmen (Madrid ESX) Dalsgaard Kristian (Madrid ESX), Recombinant subunit vaccine against porcine parvovirus.
Roof, Michael; Hayes, Phillip; Eichmeyer, Marc; Nitzel, Greg; Schaeffer, Merrill, Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs.
Roof, Michael; Hayes, Phillip; Eichmeyer, Marc; Nitzel, Greg; Schaeffer, Merrill, Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs.
Roof, Michael; Hayes, Phillip; Eichmeyer, Marc; Nitzel, Greg; Schaeffer, Merrill, Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs.
Roof, Michael; Hayes, Phillip; Eichmeyer, Marc; Nitzel, Greg; Schaeffer, Merrill, Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs.
Roof, Michael; Hayes, Phillip; Eichmeyer, Marc; Nitzel, Greg; Schaeffer, Merrill, Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs.
Tartaglia James ; Cox William I. ; Gettig Russell Robert ; Martinez Hector ; Paoletti Enzo ; Pincus Steven E., Vectors having enhanced expression, and methods of making and uses thereof.
Tartaglia James ; Jacobs Bertram L. ; Goebel Scott J. ; Cox William I. ; Gettig Russell Robert ; Pincus Steven E. ; Paoletti Enzo, Vectors having enhanced expression, and methods of making and uses thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.